CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo tackles Hard-to-Treat prostate cancer
Disease control CompletedThis study tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a hormone therapy (enzalutamide) in 7 patients with metastatic castration-resistant prostate cancer that had stopped responding to other treatments. The goal was to see if this mix could …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo therapy shows promise for hard-to-treat prostate cancer
Disease control CompletedThis study tested whether adding targeted radiation to a hormone-blocking drug (apalutamide) helps control prostate cancer that has stopped responding to standard hormone therapy and spread to a few spots. Twenty-six men with castration-resistant prostate cancer took part. The ma…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Hormone combo shows promise against resistant prostate cancer
Disease control CompletedThis study tested a new combination treatment for men with prostate cancer that stopped responding to standard hormone therapy. The treatment uses testosterone (given as shots) and a drug called olaparib to damage cancer cells' DNA, making it harder for them to survive. 36 men to…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug (AZD8186) combined with chemotherapy (docetaxel) in 23 people with advanced solid tumors that have certain gene mutations (PTEN or PIK3CB). The main goals were to find the best dose and check for side effects. The study was completed, but …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:08 UTC